SCHEMBL3883356

SCHEMBL3883356

CCOC(=O)c1cnc2ccc(/C=S3/CC(=O)N=C3N[C@@H]3C[C@H]3c3ccccc3)cc2c1OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.38
ALDH1A1 P00352 6/20 0.38
LMNA P02545 4/20 0.38
HPGD P15428 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
NPSR1 Q6W5P4 3/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
ATM Q13315 1/20 0.35
TP53 P04637 3/20 0.35
NMT1 P30419 2/20 0.34
PKM P14618 1/20 0.34
EGFR P00533 1/20 0.34
SRC P12931 1/20 0.34
NMT2 O60551 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3948070 0.93 EGFR (0.35) MAPTALDH1A1LMNAHPGDL3MBTL1
SCHEMBL3884489 0.89 EGFR (0.34) KDM4EEGFRSRC
SCHEMBL3884015 0.86 EGFR (0.40) EGFRSRC
SCHEMBL3880236 0.85 EGFR (0.47) EGFRSRC
SCHEMBL3880153 0.84 EGFR (0.39) EGFRSRC
SCHEMBL3881229 0.83 EGFR (0.38) EGFRSRC
SCHEMBL3880451 0.81 EGFR (0.39) EGFRSRC
SCHEMBL3882523 0.81 EGFR (0.39) NPSR1SMN1; SMN2EGFRSRC
SCHEMBL14452565 0.81 MAPT (0.39) MAPTALDH1A1LMNAHPGDL3MBTL1
SCHEMBL3880080 0.80 EGFR (0.38) EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771443-B1 QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-7250515-B2 Thiazolinone 3,4-disubstituted quinolines HOFFMAN-LA ROCHE INC. (US) 2007-07-31 US claimed
US-20060004046-A1 Thiazolinone 3,4-disubstituted quinolines CHEN LI 2006-01-05 US claimed
EP-1771443-B1 QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
US-7250515-B2 Thiazolinone 3,4-disubstituted quinolines HOFFMAN-LA ROCHE INC. (US) 2007-07-31 US disclosed
US-20060004046-A1 Thiazolinone 3,4-disubstituted quinolines CHEN LI 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004046-A1 Thiazolinone 3,4-disubstituted quinolines CDK1, CDK17, CDK14 MAPT 2606/4885ALDH1A1 3840/4885LMNA 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.